As a prognostic biomarker and therapeutic target, the mutation status of KMT2D can serve as an indicator for prognosis assessment in lymphoma patients, with its mutations being associated with advanced disease, relapse risk, and poor prognosis. The gene discussed is KMT2D; the disease is lymphoma.